YU88602A - Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same - Google Patents

Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same

Info

Publication number
YU88602A
YU88602A YU88602A YUP88602A YU88602A YU 88602 A YU88602 A YU 88602A YU 88602 A YU88602 A YU 88602A YU P88602 A YUP88602 A YU P88602A YU 88602 A YU88602 A YU 88602A
Authority
YU
Yugoslavia
Prior art keywords
pharmaceutical formulation
substance
hmg
chemical synthesis
coa reductase
Prior art date
Application number
YU88602A
Other languages
Serbo-Croatian (sh)
Inventor
Zlatko Pflaum
Janez Kere
Original Assignee
Lek Pharmaceuticals D.D.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals D.D. filed Critical Lek Pharmaceuticals D.D.
Publication of YU88602A publication Critical patent/YU88602A/en

Links

Abstract

Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, and some are obtained by treating the fermentation products using the methods of chemical synthesis or they are the products of total chemical synthesis. The aforementioned active substances may be destabilised by the environmental factors, their degradation may also be accelerated by interactions with other pharmaceutical ingredients, such as fillers, binders, lubricants, glidants and disintegrating agents, therefore the pharmaceutical ingredients and the process for preparation of the pharmaceutical formulation should be meticulously chosen to avoid the aforementioned undesired interactions and reactions. The present invention relates to a HMG-CoA reductase inhibitor which is stabilized by forming a homogeneous composition with a buffering substance or a basifying substance. This homogeneous composition is suitably used as the active substance in a pharmaceutical formulation for the treatment of hypercholesterolemia and hyperlipidemia.
YU88602A 2000-06-09 2000-06-09 Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same YU88602A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
YU88602 2000-06-09

Publications (1)

Publication Number Publication Date
YU88602A true YU88602A (en) 2006-05-25

Family

ID=47748802

Family Applications (1)

Application Number Title Priority Date Filing Date
YU88602A YU88602A (en) 2000-06-09 2000-06-09 Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same

Country Status (1)

Country Link
YU (1) YU88602A (en)

Similar Documents

Publication Publication Date Title
PL362764A1 (en) Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
NZ511260A (en) Stable pharmaceutical formulation comprising a HMG-CoA reductase inhibitor
IL187261A0 (en) Crystals of the sodium salt of pravastatin
IS5891A (en) New salts of HMG-CoA reductase inhibitors
ATE284396T1 (en) METHOD FOR PROVIDING HIGH PURITY HMG-COA REDUCTASE INHIBITORS
WO2000048626A3 (en) Aerosol compositions of hmg-coa reductase inhibitors for inhibiting inflammation associated with pulmonary disease
IL141785A0 (en) A pharmaceutical composition containing an ap2 inhibitor
AU1510800A (en) Process for the preparation of simvastatin and analogs thereof
AU2000250960A1 (en) Stable pharmaceutical product and formulation
YU88602A (en) Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
NZ535910A (en) Preparation of amorphous HMG-CoA reductase inhibitors and hydrates thereof by dissolving a heterogeneous mixture of the enzyme in a hydroxylic solvent and freeze drying
RU2309141C2 (en) AMORPHOUS HMG-KoA REDUCTASE INHIBITORS AND A METHOD FOR PREPARATION THEREOF
CO5611117A2 (en) COMBINATION OF ORGANIC COMPOUNDS